Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit

References

• CherMLTowlerDARafiiSCancer interaction with the bone microenvironment: A workshop of the National Institutes of Health Tumor Microenvironment Study SectionAm J Pathol20061681405141216651608
   PubMed Web of Science ®Google Scholar
• LogothetisCJLinSHOsteoblasts in prostate cancer metastasis to boneNat Rev Cancer20055212815630412
   PubMed Web of Science ®Google Scholar
• RaoARMotiwalaHGKarimOMThe discovery of prostate-specific antigenBJU Int200810151017760888
   PubMed Web of Science ®Google Scholar
• LiljaHUlmertDVickersAJProstate-specific antigen and prostate cancer: Prediction, detection and monitoringNat Rev Cancer2008826827818337732
   PubMed Web of Science ®Google Scholar
• de BonoJSScherHIMontgomeryRBCirculating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancerClin Cancer Res2008146302630918829513
   PubMed Web of Science ®Google Scholar
• SchifferEBiomarkers for prostate cancerWorld J Urol20072555756217690889
   PubMed Web of Science ®Google Scholar
• ReynoldsMAMolecular alterations in prostate cancerCancer Lett2008271132418554779
   PubMed Web of Science ®Google Scholar
• MastersJRClinical applications of expression profiling and proteomics in prostate cancerAnticancer Res2007271273127617593619
   PubMed Web of Science ®Google Scholar
• LiszewskiKOptimizing Utilization of BiomarkersGenetic Engineering and Biotechnology News28126152009
   Google Scholar
• CornPGMethylation marks the path for biomarker development in breast cancer researchCancer Biol Ther20098232260226219901521
   PubMed Web of Science ®Google Scholar
• ThompsonTCTahirSALiLThe role of caveolin-1 in prostate cancer: Clinical implicationsProstate Cancer Prostatic Dis201013161119581923
   PubMed Web of Science ®Google Scholar
• CarverLASchnitzerJECaveolae: Mining little caves for new cancer targetsNat Rev Cancer2003357158112894245
   PubMed Web of Science ®Google Scholar
• TahirSARenCTimmeTLDevelopment of an immunoassay for serum caveolin-1: A novel biomarker for prostate cancerClin Cancer Res200393653365914506154
   PubMed Web of Science ®Google Scholar
• TahirSAYangGGoltsovAATumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancerCancer Res20086873173918245473
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin20095922524919474385
   PubMed Web of Science ®Google Scholar
• GannPHRisk factors for prostate cancerRev Urol20024Suppl 5S3S1016986064
   PubMedGoogle Scholar
• PatelARKleinEARisk factors for prostate cancerNat Clin Pract Urol20096879519198622
   PubMedGoogle Scholar
• HeronMHoyertDLMurphySLXuJKochanekKDTejada-VeraBDeaths: Final data for 2006Natl Vital Stat Rep200957113419788058
   PubMedGoogle Scholar
• CalleEERodriguezCWalker-ThurmondKThunMJOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adultsN Engl J Med20033481625163812711737
   PubMed Web of Science ®Google Scholar
• StromSSWangXPettawayCAObesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomyClin Cancer Res2005116889689416203779
   PubMed Web of Science ®Google Scholar
• XuJGillandersEMIsaacsSDGenome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer familiesProstate20035732032514601028
   PubMed Web of Science ®Google Scholar
• GaytherSAde FoyKAHarringtonPThe frequency of germline mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study CollaboratorsCancer Res2000604513451810969800
   PubMed Web of Science ®Google Scholar
• AdolfssonJCommentary: On the incidence of histological prostate cancer and the probable diagnosis of cases with tumours too small to produce symptoms or to attract attention on physical examination – the findings of Dr. Arnold Rice RichInt J Epidemiol20073628528717440029
   PubMed Web of Science ®Google Scholar
• WinklerMHLivniNMannionEMHroudaDChristmasTCharacteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimensBJU Int20079955455817407514
   PubMed Web of Science ®Google Scholar
• JohanssonJEHolmbergLJohanssonSBergstromRAdamiHOFifteen-year survival in prostate cancer. A prospective, population-based study in SwedenJAMA19972774674719020270
   PubMed Web of Science ®Google Scholar
• JohanssonJEAndrenOAnderssonSONatural history of early, localized prostate cancerJAMA20042912713271915187052
   PubMed Web of Science ®Google Scholar
• BastianPJCarterBHBjartellAInsignificant prostate cancer and active surveillance: From definition to clinical implicationsEur Urol2009551321133019286302
   PubMed Web of Science ®Google Scholar
• SaitohHHidaMShimboTNakamuraKYamagataJSatohTMetastatic patterns of prostatic cancer. Correlation between sites and number of organs involvedCancer198454307830846498785
   PubMed Web of Science ®Google Scholar
• ScherHIHellerGClinical states in prostate cancer: Toward a dynamic model of disease progressionUrology20005532332710699601
   PubMed Web of Science ®Google Scholar
• ScherHIHalabiSTannockIDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJ Clin Oncol2008261148115918309951
   PubMed Web of Science ®Google Scholar
• CatalonaWJSmithDSRatliffTLBaslerJWDetection of organ-confined prostate cancer is increased through prostate-specific antigen-based screeningJAMA19932709489547688438
   PubMed Web of Science ®Google Scholar
• Lu-YaoGLFriedmanMYaoSLUse of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testingJ Urol1997157221922229146619
   PubMed Web of Science ®Google Scholar
• D’AmicoAVWhittingtonRMalkowiczSBBiochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancerJAMA19982809699749749478
   PubMed Web of Science ®Google Scholar
• D’AmicoAVMoulJCarrollPRSunLLubeckDChenMHCancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen eraJ Clin Oncol2003212163217212775742
   PubMed Web of Science ®Google Scholar
• Bill-AxelsonAHolmbergLRuutuMRadical prostatectomy versus watchful waiting in early prostate cancerN Engl J Med20053521977198415888698
   PubMed Web of Science ®Google Scholar
• AndrioleGLCrawfordEDGrubbRLIIIMortality results from a randomized prostate-cancer screening trialN Engl J Med20093601310131919297565
   PubMed Web of Science ®Google Scholar
• SchroderFHHugossonJRoobolMJScreening and prostate-cancer mortality in a randomized European studyN Engl J Med20093601320132819297566
   PubMed Web of Science ®Google Scholar
• AutierPBoniolMHeryCMasuyerEFerlayJCancer survival statistics should be viewed with cautionLancet Oncol200781050105218054874
   PubMed Web of Science ®Google Scholar
• AranhaOVaishampayanUPSA relapse prostate cancer: The importance of tailored therapyUrol Oncol200422626914969807
   PubMed Web of Science ®Google Scholar
• ThompsonIMTangenCMParadeloJAdjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trialJ Urol200918195696219167731
   PubMed Web of Science ®Google Scholar
• MessingEMManolaJSarosdyMWildingGCrawfordEDTrumpDImmediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancerN Engl J Med19993411781178810588962
   PubMed Web of Science ®Google Scholar
• PilepichMVWinterKLawtonCAAndrogen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31Int J Radiat Oncol Biol Phys2005611285129015817329
   PubMed Web of Science ®Google Scholar
• PoundCRPartinAWEisenbergerMAChanDWPearsonJDWalshPCNatural history of progression after PSA elevation following radical prostatectomyJAMA19992811591159710235151
   PubMed Web of Science ®Google Scholar
• BhandariMSCrookJHussainMShould intermittent androgen deprivation be used in routine clinical practice?J Clin Oncol2005238212821816278475
   PubMed Web of Science ®Google Scholar
• CrawfordEDHormonal therapy in prostate cancer: Historical approachesRev Urol20046Suppl 7S3S1116985934
   PubMedGoogle Scholar
• FeldmanBJFeldmanDThe development of androgen-independent prostate cancerNat Rev Cancer20011344511900250
   PubMed Web of Science ®Google Scholar
• ScherHISawyersCLBiology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axisJ Clin Oncol2005238253826116278481
   PubMed Web of Science ®Google Scholar
• Van AllenEMRyanCJNovel secondary hormonal therapy in advanced prostate cancer: An updateCurr Opin Urol20091931532119342958
   PubMed Web of Science ®Google Scholar
• TannockIFdeWRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med20043511502151215470213
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med20043511513152015470214
   PubMed Web of Science ®Google Scholar
• ManneUSrivastavaRGSrivastavaSRecent advances in biomarkers for cancer diagnosis and treatmentDrug Discov Today20051096597616023055
   PubMed Web of Science ®Google Scholar
• SawyersCLThe cancer biomarker problemNature200845254855218385728
   PubMed Web of Science ®Google Scholar
• BalkSPKoYJBubleyGJBiology of prostate-specific antigenJ Clin Oncol20032138339112525533
   PubMed Web of Science ®Google Scholar
• StameyTAYangNHayARMcNealJEFreihaFSRedwineEProstate-specific antigen as a serum marker for adenocarcinoma of the prostateN Engl J Med19873179099162442609
   PubMed Web of Science ®Google Scholar
• PartinAWKattanMWSubongENCombination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional updateJAMA1997277144514519145716
   PubMed Web of Science ®Google Scholar
• MakarovDVTrockBJHumphreysEBUpdated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005Urology2007691095110117572194
   PubMed Web of Science ®Google Scholar
• D’AmicoAVWhittingtonRMalkowiczSBBiochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancerJAMA19982809699749749478
   PubMed Web of Science ®Google Scholar
• HernandezDJNielsenMEHanMPartinAWContemporary evaluation of the D’amico risk classification of prostate cancerUrology20077093193518068450
   PubMed Web of Science ®Google Scholar
• KattanMWWheelerTMScardinoPTPostoperative nomogram for disease recurrence after radical prostatectomy for prostate cancerJ Clin Oncol1999171499150710334537
   PubMed Web of Science ®Google Scholar
• GraefenMKarakiewiczPICagiannosIValidation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancerJ Clin Oncol20022095195611844816
   PubMed Web of Science ®Google Scholar
• StarkJRPernerSStampferMJGleason score and lethal prostate cancer: Does 3 + 4 = 4 + 3?J Clin Oncol2009273459346419433685
   PubMed Web of Science ®Google Scholar
• NavoneNMLabateMETroncosoPp53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potentialJ Urol199916130430810037428
   PubMed Web of Science ®Google Scholar
• McDonnellTJNavoneNMTroncosoPExpression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancerJ Urol19971575695748996359
   PubMed Web of Science ®Google Scholar
• SanchezPHernandezAMSteccaBInhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signalingProc Natl Acad Sci U S A2004101125611256615314219
   PubMed Web of Science ®Google Scholar
• ZunichSMDouglasTValdovinosMParacrine sonic hedgehog signalling by prostate cancer cells induces osteoblast differentiationMol Cancer200981219254376
   PubMed Web of Science ®Google Scholar
• PoundCRBrawerMKPartinAWEvaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancerRev Urol20013728416985694
   PubMedGoogle Scholar
• PartinAWPearsonJDLandisPKEvaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasesUrology1994436496597513108
   PubMed Web of Science ®Google Scholar
• PatelADoreyFFranklinJdeKernionJBRecurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigenJ Urol1997158144114459302139
   PubMed Web of Science ®Google Scholar
• CannonGMJrWalshPCPartinAWPoundCRProstate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancerUrology200362Suppl 12814747037
   PubMed Web of Science ®Google Scholar
• D’AmicoAVMoulJWCarrollPRSunLLubeckDChenMHSurrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapyJ Natl Cancer Inst2003951376138313130113
   PubMed Web of Science ®Google Scholar
• StewartAJScherHIChenMHProstate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostatespecific antigen failureJ Clin Oncol2005236556656016170163
   PubMed Web of Science ®Google Scholar
• HussainMTangenCMHiganoCAbsolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162)J Clin Oncol2006243984399016921051
   PubMed Web of Science ®Google Scholar
• HussainMGoldmanBTangenCProstate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916J Clin Oncol2009272450245619380444
   PubMed Web of Science ®Google Scholar
• BubleyGJCarducciMDahutWEligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working GroupJ Clin Oncol1999173461346710550143
   PubMed Web of Science ®Google Scholar
• PetrylakDPAnkerstDPJiangCSEvaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16J Natl Cancer Inst20069851652116622120
   PubMedGoogle Scholar
• ShaulPWAndersonRGRole of plasmalemmal caveolae in signal transductionAm J Physiol1998275L843L8519815100
   PubMedGoogle Scholar
• SternbergPWSchmidSLCaveolin, cholesterol and Ras signallingNat Cell Biol19991E35E3710559891
   PubMed Web of Science ®Google Scholar
• AndersonRGJacobsonKA role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domainsScience20022961821182512052946
   PubMed Web of Science ®Google Scholar
• CarverLASchnitzerJEAndersonRGMohlaSRole of caveolae and lipid rafts in cancer: Workshop summary and future needsCancer Res2003636571657414583447
   PubMed Web of Science ®Google Scholar
• LiSCouetJLisantiMPSrc tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinasesJ Biol Chem199627129182291908910575
   PubMed Web of Science ®Google Scholar
• ShatzMLiscovitchMCaveolin-1: A tumor-promoting role in human cancerInt J Radiat Biol20088417718918300018
   PubMed Web of Science ®Google Scholar
• GlenneyJRJrTyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virusJ Biol Chem198926420163201662479645
   PubMed Web of Science ®Google Scholar
• RazaniBSchlegelALiuJLisantiMPCaveolin-1, a putative tumour suppressor geneBiochem Soc Trans20012949449911498016
   PubMed Web of Science ®Google Scholar
• WilliamsTMLisantiMPCaveolin-1 in oncogenic transformation, cancer, and metastasisAm J Physiol Cell Physiol2005288C494C50615692148
   PubMed Web of Science ®Google Scholar
• RajjayabunPHGargSDurkanGCCharltonRRobinsonMCMellonJKCaveolin-1 expression is associated with high-grade bladder cancerUrology20015881181411711373
   PubMed Web of Science ®Google Scholar
• KatoKHidaYMiyamotoMOverexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stageCancer20029492993311920460
   PubMed Web of Science ®Google Scholar
• YangGTruongLDTimmeTLElevated expression of caveolin is associated with prostate and breast cancerClin Cancer Res19984187318809717814
   PubMed Web of Science ®Google Scholar
• YangGTruongLDWheelerTMThompsonTCCaveolin-1 expression in clinically confined human prostate cancer: A novel prognostic markerCancer Res1999595719572310582690
   PubMed Web of Science ®Google Scholar
• KaramJALotanYRoehrbornCGAshfaqRKarakiewiczPIShariatSFCaveolin-1 overexpression is associated with aggressive prostate cancer recurrenceProstate20076761462217299799
   PubMed Web of Science ®Google Scholar
• LiLRenCHTahirSARenCThompsonTCCaveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2AMol Cell Biol2003239389940414645548
   PubMed Web of Science ®Google Scholar
• NasuYTimmeTLYangGSuppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cellsNat Med19984106210649734401
   PubMed Web of Science ®Google Scholar
• LiLYangGEbaraSCaveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cellsCancer Res2001614386439211389065
   PubMed Web of Science ®Google Scholar
• TahirSAYangGEbaraSSecreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancerCancer Res2001613882388511358800
   PubMed Web of Science ®Google Scholar
• EngelmanJAZhangXLLisantiMPGenes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancersFEBS Lett19984364034109801158
   PubMed Web of Science ®Google Scholar
• NupponenNNKakkolaLKoivistoPVisakorpiTGenetic alterations in hormone-refractory recurrent prostate carcinomasAm J Pathol19981531411489665474
   PubMed Web of Science ®Google Scholar
• CuiJRohrLRSwansonGSpeightsVOMaxwellTBrothmanARHypermethylation of the caveolin-1 gene promoter in prostate cancerProstate20014624925611170154
   PubMed Web of Science ®Google Scholar
• BachmannNHaeuslerJLuedekeMExpression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinomaCancer Genet Cytogenet200818210311018406871
   PubMedGoogle Scholar
• GandelliniPFoliniMLongoniNmiR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase CepsilonCancer Res2009692287229519244118
   PubMed Web of Science ®Google Scholar
• XinLTeitellMALawsonDAKwonAMellinghoffIKWitteONProgression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptorProc Natl Acad Sci U S A20061037789779416682621
   PubMed Web of Science ®Google Scholar
• CantleyLCNeelBGNew insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathwayProc Natl Acad Sci U S A1999964240424510200246
   PubMed Web of Science ®Google Scholar
• LiLRenCYangGGoltsovAATabataKThompsonTCCaveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cellsMol Cancer Res200971781179119903767
   PubMed Web of Science ®Google Scholar
• TahirSAParkSThompsonTCCaveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cellsCancer Biol Ther20098
   Web of Science ®Google Scholar
• SchlegelAArvanPLisantiMPCaveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulumJ Biol Chem20012764398440811078729
   PubMed Web of Science ®Google Scholar
• LlorenteAde MarcoMCAlonsoMACaveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell lineJ Cell Sci20041175343535115466889
   PubMed Web of Science ®Google Scholar
• LuQZhangJAllisonRIdentification of extracellular delta-catenin accumulation for prostate cancer detectionProstate20096941141819116988
   PubMed Web of Science ®Google Scholar
• WoodmanSEAshtonAWSchubertWCaveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuliAm J Pathol20031622059206812759260
   PubMed Web of Science ®Google Scholar
• YangGAddaiJWheelerTMCorrelative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesisHum Pathol2007381688169517707459
   PubMed Web of Science ®Google Scholar
• BonoAVCelatoNCovaVSalvadoreMChinettiSNovarioRMicrovessel density in prostate carcinomaProstate Cancer Prostatic Dis2002512312712497001
   PubMed Web of Science ®Google Scholar
• TahirSAFrolovAHayesTGPreoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohortClin Cancer Res2006124872487516914574
   PubMed Web of Science ®Google Scholar